70 results on '"Vanderstichele, Hugo"'
Search Results
2. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
3. Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays
4. How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio
5. Accelerating drug development for Alzheimer's disease through the use of data standards
6. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition
7. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
8. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
9. CSF biomarker variability in the Alzheimer's Association quality control program
10. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients
11. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
12. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers
13. Added diagnostic value of CSF biomarkers in differential dementia diagnosis
14. Evaluation of plasma Aβ 40 and Aβ 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
15. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
16. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study
17. LAB-RELATED PRE-ANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS
18. Evidence That Aβ42 Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype
19. IMPROVED DIAGNOSTIC ACCURACY USING THE CEREBROSPINAL FLUID AMYLOID BETA 1-42/1-40 RATIO
20. MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON’S DISEASE
21. TOWARD RE-CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID
22. CSF BIOMARKERS OF SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IMPROVE DIAGNOSTIC CLASSIFICATION OF MCI AND AD AND CORRELATE WITH COGNITION
23. THE CSF SYNAPTIC BIOMARKER BACE1 CORRELATES WITH COGNITION IN MCI AND ALZHEIRMER DISEASE
24. CSF BIOMARKERS OF AMYLOID, TAU AND SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IN CSF AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD
25. CHARACTERIZATION AND TRANSFER OF A NOVEL PLASMA Aβ1-42/Aβ1-40 SIMOA ASSAY FOR INTEGRATION INTO THE CLINIC
26. PLASMA AMYLOID BETA 1-42 AND 1-40 MEASURED BY A NOVEL SIMOA ASSAY AS A DIAGNOSTIC TOOL FOR ALZHEIMER'S DISEASE PATHOLOGY
27. CSF BIOMARKERS RELATED TO NEURODEGENERATION AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND ELDERLY CONTROLS
28. PLASMA AMYLOID β LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY
29. A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS
30. HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
31. A UNIFIED PRE-ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS
32. C-REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY
33. ANALYTICAL VALIDATION OF FULLY AUTOMATED CHEMILUMINESCENCE IMMUNOASSAYS FOR CSF BETA-AMYLOID 1-40 AND 1-42 ANALYSIS FOR USE IN CLINICAL TRIALS
34. EVALUATION OF CERTIFIED REFERENCE MATERIALS FOR BETA-AMYLOID 1-42 IN EUROIMMUN BETA-AMYLOID 1-42 ELISA AND CHLIA
35. USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
36. PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
37. ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE
38. TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS
39. ASSOCIATION BETWEEN NOCTURNAL AMYLOID BETA FLUCTUATIONS AND SLEEP
40. SYNAPTIC MARKERS IN LIQUOR INVERSELY CORRELATE WITH GRAY MATTER VOLUME IN COGNITIVELY HEALTHY INDIVIDUALS
41. THE CSF Aβ(1-42)/Aβ(1-40) RATIO IMPROVES THE CLINICAL UTILITY OF Aβ(1-42) BY ITS IMPACT AT ANALYTICAL AND CLINICAL LEVELS
42. ANALYTICAL PERFORMANCE CHARACTERISTICS OF A PROTOTYPE IMMUNOASSAY FOR QUANTIFICATION OF ALPHA-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID
43. ANALYTICAL PERFORMANCE CHARACTERISTICS OF A NOVEL IMMUNOASSAY FOR THE QUANTIFICATION OF BACE-1 IN HUMAN CEREBROSPINAL FLUID
44. A NOVEL COLORIMETRIC ELISA FOR QUANTIFICATION OF TAU, PHOSPHORYLATED AT THREONINE 181, IN CEREBROSPINAL FLUID
45. DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, α-SYNUCLEIN AND ALZHEIMER’S DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER’S DEMENTIA
46. STANDARDIZATION OF PRE-ANALYTICAL PROCEDURES FOR COLLECTION AND STORAGE OF CSF FOR THE MEASUREMENT OF NEUROGRANIN TRUNC P75 AND A-SYNUCLEIN
47. PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR AB1-42
48. SUPPRESSION OF TAU INCREASE IN CEREBROSPINAL FLUID OF APP TRANSGENIC MICE PROVIDES EVIDENCE FOR DOWNSTREAM EFFECT OF BACE1 INHIBITION
49. PERFORMANCE TESTING AND ANALYTICAL VALIDATION OF NEW ELISAS FOR B-AMYLOID ISOFORMS (AB(1-38), AB(1-40), AB(1-42)) IN PLASMA
50. PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.